HO-1/BVR-A system analysis in plasma from probable Alzheimer's disease and mild cognitive impairment subjects: A potential biochemical marker for the prediction of the disease

Journal of Alzheimer's Disease

Volumn 32, Issue 2, 2012, Pages 277-289

  Di Domenico, Fabio ^a   Baroneb, Eugenio ^b   Mancuso, Cesare ^b   Perluigi, Marzia ^a   Cocciolo, Annalisa ^a   Mecocci, Patrizia ^c   Butterfield, D Allan ^d   Coccia, Raffaella ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer disease's; bilirubin; biliverdin reductase A; heme oxygenase 1; oxidative nitrosative stress

Indexed keywords

3 NITROTYROSINE; BILIRUBIN; BILIVERDIN; BILIVERDIN REDUCTASE A; HEME OXYGENASE 1; PHOSPHOTYROSINE; PROTEOME; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HIPPOCAMPUS; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; OXIDATION; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CARBONYLATION; PROTEIN EXPRESSION; STRESS;

EID: 84867489401     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-121045     Document Type: Article

References (69)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M, Alzheimer's Disease I (2005) Global prevalence of dementia: A Delphi consensus study. Lancet 366, 2112- 2117.
2. DeKosky ST, MarekK(2003) Looking backward tomove forward: Early detection of neurodegenerative disorders. Science 302, 830-834.
3. Chong MS, Sahadevan S (2005) Preclinical Alzheimer's disease: Diagnosis and prediction of progression. Lancet Neurol 4, 576-579.
4. Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 45, 358-368.
5. Morris JC, Cummings J (2005) Mild cognitive impairment (MCI) represents early-stage Alzheimer's disease. J Alzheimers Dis 7, 235-239; discussion 255-262.
6. Storandt M, Grant EA, Miller JP, Morris JC (2002) Rates of progression in mild cognitive impairment and early Alzheimer's disease. Neurology 59, 1034-1041
7. Pratico D (2008) Oxidative stress hypothesis in Alzheimer's disease: A reappraisal. Trends Pharmacol Sci 29, 609- 615.
8. Markesbery WR (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 23, 134-147.
9. Sultana R, Butterfield DA (2010) Role of oxidative stress in the progression of Alzheimer's disease. J Alzheimers Dis 19, 341-353.
10. Butterfield DA, Perluigi M, Sultana R (2006) Oxidative stress in Alzheimer's disease brain: New insights from redox proteomics. Eur J Pharmacol 545, 39-50.
11. Perluigi M, Sultana R, Cenini G, Di Domenico F, Memo M, Pierce WM, Coccia R, Butterfield DA (2009) Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesis. Proteomics Clin Appl 3, 682-693.
12. Markesbery WR, Lovell MA (1998) Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19, 33- 36.
13. Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA (2003) Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 85, 1394-1401.
14. Mecocci P, MacGarvey U, Beal MF (1994) Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 36, 747-751.
15. Kapitulnik J, Maines MD (2009) Pleiotropic functions of biliverdin reductase: Cellular signaling and generation of cytoprotective and cytotoxic bilirubin. Trends Pharmacol Sci 30, 129-137.
16. Maines MD (2005) New insights into biliverdin reductase functions: Linking heme metabolism to cell signaling. Physiology (Bethesda) 20, 382-389.
17. Lerner-Marmarosh N, Shen J, Torno MD, Kravets A, Hu Z, Maines MD (2005) Human biliverdin reductase: A member of the insulin receptor substrate family with serine/ threonine/tyrosine kinase activity. Proc Natl Acad Sci U S A 102, 7109-7114.
18. Mancuso C, Capone C, Ranieri SC, Fusco S, Calabrese V, Eboli ML, Preziosi P, Galeotti T, Pani G (2008) Bilirubin as an endogenous modulator of neurotrophin redox signaling. J Neurosci Res 86, 2235-2249.
19. Fernandes A, Falcao AS, Silva RF, Brito MA, Brites D (2007) MAPKs are key players in mediating cytokine release and cell death induced by unconjugated bilirubin in cultured rat cortical astrocytes. Eur J Neurosci 25, 1058- 1068.
20. Calabrese V, Sultana R, Scapagnini G, Guagliano E, Sapienza M, Bella R, Kanski J, Pennisi G, Mancuso C, Stella AM, Butterfield DA (2006), Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid Redox Signal 8, 1975- 1986.
21. Schipper HM, Bennett DA, Liberman A, Bienias JL, Schneider JA, Kelly J, Arvanitakis Z (2006) Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment. Neurobiol Aging 27, 252-261.
22. Takeda A, Itoyama Y, Kimpara T, Zhu X, Avila J, Dwyer BE, Perry G, Smith MA (2004) Heme catabolism and heme oxygenase in neurodegenerative disease. Antioxid Redox Signal 6, 888-894.
23. Barone E, Di Domenico F, Cenini G, Sultana R, Coccia R, Preziosi P, Perluigi M, Mancuso C, Butterfield DA (2011) Oxidative and nitrosative modifications of biliverdin reductase-A in the brain of subjects with Alzheimer's disease and amnestic mild cognitive impairment. J Alzheimers Dis 25, 623-633.
24. Barone E, Di Domenico F, Cenini G, Sultana R, Cini C, Preziosi P, Perluigi M, Mancuso C, Butterfield DA (2011) Biliverdin reductase-a protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment. Biochim Biophys Acta 1812, 480- 487.
25. Di Domenico F, Sultana R, Tiu GF, Scheff NN, Perluigi M, Cini C, Butterfield DA (2010) Protein levels of heat shock proteins 27, 32, 60, 70, 90 and thioredoxin-1 in amnestic mild cognitive impairment: An investigation on the role of cellular stress response in the progression of Alzheimer disease. Brain Res 1333, 72-81.
26. Barone E, Di Domenico F, Sultana R, Coccia R, Mancuso C, Perluigi M, Butterfield DA (2012) Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment. Free Radic Biol Med 52, 2292-2301.
27. Schipper HM, ChertkowH, Mehindate K, Frankel D, Melmed C, Bergman H (2000) Evaluation of heme oxygenase-1 as a systemic biological marker of sporadic AD. Neurology 54, 1297-1304.
28. Mateo I, Infante J, Sanchez-Juan P, Garcia-Gorostiaga I, Rodriguez-Rodriguez E, Vazquez-Higuera JL, Berciano J, Combarros O (2010) Serum heme oxygenase-1 levels are increased in Parkinson's disease but not in Alzheimer's disease. Acta Neurol Scand 121, 136-138.
29. Mueller C, Zhou W, Vanmeter A, Heiby M, Magaki S, Ross MM, Espina V, Schrag M, Dickson C, Liotta LA, Kirsch WM (2010) The heme degradation pathway is a promising serum biomarker source for the early detection of Alzheimer's disease. J Alzheimers Dis 19, 1081-1091.
30. Song F, Poljak A, Smythe GA, Sachdev P (2009) Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. Brain Res Rev 61, 69-80.
31. Mulder C,VerweyNA, van der FlierWM,Bouwman FH,Kok A, van Elk EJ, Scheltens P, BlankensteinMA(2010) Amyloidbeta (1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 56, 248-253.
32. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR Jr, Jagust WJ, Shaw LM, Toga AW, Trojanowski JQ, Weiner MW (2010) Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization. Neurology 74, 201-209.
33. Aluise CD, Sowell RA, Butterfield DA (2008) Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease. Biochim Biophys Acta 1782, 549-558.
34. Righetti PG, Castagna A, Antonioli P, Boschetti E (2005) Prefractionation techniques in proteome analysis: The mining tools of the third millennium. Electrophoresis 26, 297-319.
35. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
36. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST (2001) Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Report of the Quality StandardsSubcommittee of the American Academy of Neurology. Neurology 56, 1133-1142.
37. Zafrilla P, Mulero J, Xandri JM, Santo E, Caravaca G, Morillas JM (2006) Oxidative stress in Alzheimer patients in different stages of the disease. Curr Med Chem 13, 1075-1083.
38. Grossman M, Farmer J, Leight S, Work M, Moore P, Van Deerlin V, Pratico D, Clark CM, Coslett HB, Chatterjee A, Gee J, Trojanowski JQ, Lee VM (2005) Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann Neurol 57, 721-729.
39. Dildar K, Sinem F, Gokhan E, Orhan Y, FilizM(2010) Serum nitrosative stress levels are increased in Alzheimer disease but not in vascular dementia. Alzheimer Dis Assoc Disord 24, 194-197.
40. Korolainen MA, Nyman TA, Nyyssonen P, Hartikainen ES, Pirttila T (2007) Multiplexed proteomic analysis of oxidation and concentrations of cerebrospinal fluid proteins inAlzheimer disease. Clin Chem 53, 657-665.
41. Skoumalova A, Ivica J, Santorova P, Topinkova E, Wilhelm J (2011) The lipid peroxidation products as possible markers of Alzheimer's disease in blood. Exp Gerontol 46, 38-42.
42. Aluise CD, Robinson RA, Beckett TL, Murphy MP, Cai J, Pierce WM, Markesbery WR, Butterfield DA (2010) Preclinical Alzheimer disease: Brain oxidative stress, Abeta peptide and proteomics. Neurobiol Dis 39, 221-228.
43. Butterfield DA, Stadman ER (1997) Protein oxidation processes in aging brain. In: Advances in Cell Aging and Gerontology, Timiras PS, Bittar EE, Eds. Elsevier B.V., pp. 161-191.
44. Montine TJ, Quinn JF, Milatovic D, Silbert LC, Dang T, Sanchez S, Terry E, Roberts LJ 2nd, Kaye JA, Morrow JD (2002) Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol 52, 175-179.
45. Irizarry MC, Yao Y, Hyman BT, Growdon JH, Pratico D (2007) Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease. Neurodegener Dis 4, 403-405.
46. Mufson EJ, Leurgans S (2010) Inability of plasma and urine F2A-isoprostane levels to differentiate mild cognitive impairment from Alzheimer's disease. Neurodegener Dis 7, 139-142.
47. Padurariu M, Ciobica A, Hritcu L, Stoica B, Bild W, Stefanescu C (2010) Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 469, 6-10.
48. Pratico D, Clark CM, Lee VM, Trojanowski JQ, Rokach J, FitzGerald GA (2000) Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: Correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 48, 809- 812.
49. Pratico D, MY Lee V, Trojanowski JQ, Rokach J, Fitzgerald GA (1998) Increased F2-isoprostanes in Alzheimer's disease: Evidence for enhanced lipid peroxidation in vivo. FASEB J 12, 1777-1783.
50. Choi J, Malakowsky CA, Talent JM, Conrad CC, Gracy RW (2002) Identification of oxidized plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun 293, 1566-1570.
51. Conrad CC, Marshall PL, Talent JM, Malakowsky CA, Choi J, GracyRW(2000) Oxidized proteins in Alzheimer's plasma. Biochem Biophys Res Commun 275, 678-681.
52. Yu HL, Chertkow HM, Bergman H, Schipper HM (2003) Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma. Proteomics 3, 2240-2248.
53. Korolainen MA, Pirttila T (2009) Cerebrospinal fluid, serum and plasma protein oxidation in Alzheimer's disease. Acta Neurol Scand 119, 32-38.
54. Kim TS, Pae CU, Yoon SJ, JangWY, Lee NJ, Kim JJ, Lee SJ, Lee C, Paik IH, LeeCU(2006) Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry 21, 344-348.
55. Mancuso C, Bonsignore A, Capone C, Di Stasio E, Pani G (2006) Albumin-bound bilirubin interacts with nitric oxide by a redox mechanism. Antioxid Redox Signal 8, 487-494.
56. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN (1987) Bilirubin is an antioxidant of possible physiological importance. Science 235, 1043-1046.
57. Stocker R, Glazer AN, Ames BN (1987) Antioxidant activity of albumin-bound bilirubin. Proc Natl Acad Sci U S A 84, 5918-5922.
58. Dore S, Takahashi M, Ferris CD, Zakhary R, Hester LD, Guastella D, Snyder SH (1999) Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury. Proc Natl Acad Sci U S A 96, 2445-2450.
59. Barone E, Trombino S, Cassano R, Sgambato A, De Paola B, Di Stasio E, Picci N, Preziosi P, Mancuso C (2009) Characterization of the S-denitrosylating activity of bilirubin. J Cell Mol Med 13, 2365-2375.
60. Kapitulnik J (2004) Bilirubin: An endogenous product of heme degradation with both cytotoxic and cytoprotective properties. Mol Pharmacol 66, 773-779.
61. Manolio TA, Burke GL, Savage PJ, Jacobs DR Jr, Sidney S, Wagenknecht LE, Allman RM, Tracy RP (1992) Sex- and race-related differences in liver-associated serum chemistry tests in young adults in the CARDIA study. Clin Chem 38, 1853-1859.
62. White GL Jr, Nelson JA, Pedersen DM, Ash KO (1981) Fasting and gender (and altitude?) influence reference intervals for serum bilirubin in healthy adults. Clin Chem 27, 1140-1142.
63. Hale WE, Stewart RB, Marks RG (1983) Haematological and biochemical laboratory values in an ambulatory elderly population: An analysis of the effects of age, sex and drugs. Age Ageing 12, 275-284.
64. Ishizuka K, Kimura T, Yoshitake J, Akaike T, Shono M, Takamatsu J, Katsuragi S, Kitamura T, Miyakawa T (2002) Possible assessment for antioxidant capacity in Alzheimer's disease by measuring lymphocyte heme oxygenase-1 expression with real-time RT-PCR. Ann N Y Acad Sci 977, 173-178.
65. Maes OC, Kravitz S, Mawal Y, Su H, Liberman A, Mehindate K, Berlin D, Sahlas DJ, Chertkow HM, Bergman H, Melmed C, Schipper HM (2006) Characterization of alpha1- antitrypsin as a heme oxygenase-1 suppressor in Alzheimer plasma. Neurobiol Dis 24, 89-100.
66. SchipperHM(2007) Biomarker potential of heme oxygenase- 1 in Alzheimer's disease and mild cognitive impairment. Biomark Med 1, 375-385.
67. Barone E, Mancuso C, Di Domenico F, Sultana R, Murphy MP, Head E, Butterfield DA (2012) Biliverdin reductase-A: A novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease. J Neurochem 120, 135-146.
68. Maines MD, Mayer RD, Erturk E, Huang TJ, Disantagnese A (1999) The oxidoreductase, biliverdin reductase, is induced in human renal carcinoma-pH and cofactor-specific increase in activity. J Urol 162, 1467-1472.
69. SchipperHM(2007) The role of biologic markers in the diagnosis of Alzheimer's disease. Alzheimers Dement 3, 325-332.